An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure

Heart failure (HF) is associated with high mortality and hospitalization rates. Prior studies show that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalizations, and improves health related quality of life. However, self-care has generally been found to be poor among HF patients. This study aims to assess the feasibility, acceptance, and efficacy of an innovative, patient-centered intervention (iCardia4HF) that aims to promote adherence to HF self-care and improve patient outcomes through the use of commercially available mobile health technologies.

Study Overview

• Status: Completed
• Conditions: Heart Failure
• Intervention / Treatment: Behavioral: iCardia4HF; Other: Usual Care

Detailed Description

More than 6.5 million people have heart failure (HF) in the United States and 960,000 new cases are reported annually. HF is associated with high mortality and hospitalization rates, high costs, and poor health-related quality of life (HRQL). Despite major improvements in outcomes with medical and surgical therapy, admission rates following a HF-related hospitalization remain high with 25% of patients readmitted to the hospital within 30-days and up to 50% readmitted within 6 months. Previous research shows that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalization, and improves HRQL. However, self-care has generally been found to be poor among HF patients, particularly minority populations. Nonadherence to HF symptom monitoring and medication use is remarkably high even among recently discharged patients hospitalized due to a HF exacerbation. Recent advances in consumer-based mobile health (mHealth) technologies, such as smartphones, mobile health apps, wearable sensors, and other smart and connected health devices, offer scalable and affordable solutions for promoting better HF self-care and expanding delivery of care services to communities that are difficult to reach. However, no prior studies have assessed the impact of these technologies on HF self-care and patient outcomes.

This study aims to conduct a pilot randomized controlled trial (RCT) of a patient-centered intervention named iCardia4HF that promotes adherence to HF self-care through the use of commercial mHealth devices and app tools. iCardia4HF consists of: (1) a patient-centered mHealth app, developed in partnership with the Heart Failure Society of America, that interfaces with multiple connected health devices and comprises a number of self- monitoring, patient education, and adherence reminder tools for improving self-care; and (2) individually tailored text-messages (TMs) targeting health beliefs, self-care efficacy, and HF-knowledge. Study participants (n=92) diagnosed with HF will be randomly assigned to iCardia4HF or the control group for 12 weeks. Specific aims are to: 1) assess the feasibility and acceptance of iCardia4HF; 2) examine the preliminary efficacy of iCardia4HF on objectively assessed measures of HF self-care using real- time data from the connected health devices and app, as well as self-reported Self-Care and HRQL; track the number of hospitalizations and emergency room (ER) visits over 12 weeks; and 3) examine the mediating effect of intervention target variables (health beliefs, self-care efficacy, and HF-knowledge) and impact of independent patient factors on HF self-care.

This study represents an important step in identifying an affordable and scalable mHealth intervention that has the potential to bring about a new paradigm in self-care management of HF.

• Study Type: Interventional
• Enrollment (Actual): 89
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60612
      • University of Illinois Hospital & Health Sciences System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Chronic HF, Stage C
• ≥ 18 years of age
• Being treated with oral diuretics for heart failure
• Suboptimal HF self-care adherence (score 1 or 2 in at least two items of the Self-care of Heart Failure Index v.7.2)
• Ability to speak and read English

Exclusion Criteria:

• Planned coronary revascularization, Transcatheter Aortic Valve Implantation (TAVI), Cardiac Resynchronization Therapy (CRT) - implantation, and/or heart transplantation (HTx) within the next 3 months.
• Coronary revascularization and/or CRT-implantation within the last 30 days
• Advanced renal disease (stage IV CKD, GFR<30, or hemodialysis)
• Known alcohol or drug use
• End-stage HF (hospice candidate)
• Active cancer
• Pregnancy
• Not able to take care of self (eat, dress, walk, bath, take medications, or use the toilet)
• Discharged to or already living in a nursing home or other care facility other than home
• Cognitive impairment (MoCA score < 22).
• Prior use of study devices for self-care or participation in a similar trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: mHealth; Intervention group	Behavioral: iCardia4HF; Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge.
Active Comparator: Usual Care; Control group	Other: Usual Care; Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Medication adherence (dose count)	Percent of prescribed number of doses taken	Weeks 1 to 12
Medication adherence (dose time)	Percent of doses taken on schedule within 25% of the expected time interval	Weeks 1 to 12
Adherence to daily self-monitoring of weight	Number of days patients completed at least one measurement between 12 am and 11:59pm	Weeks 1 to 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence to daily self-monitoring of blood pressure	Number of days patients completed at least one BP measurement between 12 am and 11:59pm	Weeks 1 to 12
Adherence to self-monitoring of HF symptoms	Number of days intervention patients used the mobile app to record their HF symptoms	Weeks 1 to 12
Physical activity - Steps	Number of daily steps (measured with a Fitbit device)	Weeks 1 to 12
Moderate-to-Vigorous Physical Activity	Number of moderate-to-vigorous physical activity minutes per day (measured with a Fitbit device)	Weeks 1 to 12
Adherence to low-sodium diet	Sodium intake will be assessed with a urinary sample test	Baseline, 12 Weeks
Self-reported Self-care	Measured with the Self-Care Heart Failure Index (SCHFI) v.7.2. Each scale score ranges from 0 to 100. Higher scores indicate better self-care.	Baseline, 30 days, and 12 Weeks
Health Beliefs about Medication Compliance	Beliefs about Medication Compliance Scale (12-items)	Baseline, 30 days, and 12 Weeks
Health Beliefs about Dietary Compliance	Beliefs about Dietary Compliance Scale (12 items)	Baseline, 30 days, and 12 Weeks
Health Beliefs about Self-Monitoring Compliance	Beliefs about Self-Monitoring Scale (18 items)	Baseline, 30 days, and 12 Weeks
HF-knowledge	HF-specific knowledge will be assessed with the Dutch Heart Failure Knowledge Scale (DHFK), a 15-item questionnaire measuring general knowledge about HF, symptom recognition, and treatment (e.g. diet and fluid restriction)	Baseline, 30 days, and 12 Weeks
Health-related Quality of life (HRQoL)	HRQoL will be measured with the Kansas City Cardiomyopathy Questionnaire, which contains 23-items that can be quantified into five subscales: physical limitations, symptoms (frequency, severity, and change over time), quality of life (QoL), social interference, and self-efficacy. Lower scores indicate worse HRQoL.	Baseline, 30 days, and 12 Weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
HF-related hospitalizations	Number of patients with an event	Weeks 1 to 12
HF-related hospitalization rate	Number of hospitalizations per person	Weeks 1 to 12
All-cause hospitalizations	Number of patients with an event	Weeks 1 to 12
All-cause hospitalization rate	Number of all-cause hospitalizations per person	Weeks 1 to 12
Emergency room visits	Number of patients with an event	Weeks 1 to 12
Emergency room visit rate	Number of emergency room visits per person	Weeks 1 to 12

Collaborators and Investigators

• Sponsor: University of Illinois at Chicago
• Collaborators: National Institute of Nursing Research (NINR); Rush University Medical Center; Indiana University
• Investigators: Principal Investigator: Spyros Kitsiou, University of Illinois at Chicago

Publications and helpful links

General Publications

• Kitsiou S, Gerber BS, Kansal MM, Buchholz SW, Chen J, Ruppar T, Arrington J, Owoyemi A, Leigh J, Pressler SJ. Patient-centered mobile health technology intervention to improve self-care in patients with chronic heart failure: Protocol for a feasibility randomized controlled trial. Contemp Clin Trials. 2021 Jul;106:106433. doi: 10.1016/j.cct.2021.106433. Epub 2021 May 13.

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2020
• Primary Completion (Actual): September 30, 2022
• Study Completion (Actual): December 31, 2022

Study Registration Dates

• First Submitted: January 6, 2020
• First Submitted That Met QC Criteria: February 7, 2020
• First Posted (Actual): February 10, 2020

Study Record Updates

• Last Update Posted (Actual): April 28, 2023
• Last Update Submitted That Met QC Criteria: April 27, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: self-management; smartphone; heart failure; mHealth; wearables; text messaging; telehealth; mobile apps
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: 2019-0790; 1R21NR018281-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Final research data along with metadata and descriptors will be shared to make sharing meaningful and usable by other researchers. More specifically, we will share both de-identified individual-level data and aggregate data in the form of summary statistics and tables. For the individual-level data, we will develop a data dictionary and documentation guide to maximize the utility of the data and to help qualified researchers understand and properly use the data as needed.
• IPD Sharing Time Frame: Within 2 years after the final data collection is completed or within one year after the publication of the main outcomes manuscript (whichever comes first), we will share the final, completely de-identified dataset with the research community.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No